 |
|
Ultralow-Dose Micronized 17 -Estradiol and Bone Density and Bone Metabolism in Older Women
A Randomized Controlled Trial
Karen M. Prestwood, MD;
Anne M. Kenny, MD;
Alison Kleppinger, MS;
Martin Kulldorff, PhD
JAMA. 2003;290:1042-1048.
Context Estrogen therapy is known to prevent osteoporosis, but studies have shown that conventional doses increase adverse events. Whether lower doses, one quarter of standard treatment, prevent bone loss is not known.
Objective To examine the effect of 3 years of treatment with 0.25 mg/d of micronized 17 -estradiol on bone mineral density (BMD) and bone turnover in healthy older postmenopausal women.
Design, Setting, and Participants Randomized, double-blind, placebo-controlled trial conducted from July 24, 1998, through June 14, 2002, at a university general clinical research center in the United States. Healthy, community-dwelling women (N = 167) who were older than 65 years at enrollment.
Intervention Dosage of 0.25 mg/d of micronized 17-estradiol (n = 83) or placebo (n = 84); all women who had not had a hysterectomy received 100 mg/d of oral micronized progesterone for 2-week periods every 6 months.
Main Outcome Measures The BMD of the hip, spine, wrist, and total body measured annually for 3 years. Serum and urine biochemical markers of bone resorption and formation and sex hormones were measured at baseline, 3 months, and during years 1 and 3 of treatment.
Results Mean BMD increased at all sites for participants taking low-dose estrogen (17-estradiol) compared with placebo (P<.001). Compared with participants receiving placebo, participants taking low-dose estrogen had BMD increases of 2.6% for the femoral neck; 3.6%, total hip; 2.8%, spine; and 1.2%, total body. Markers of bone turnover, N-telopeptides of type 1 collagen, and bone alkaline phosphatase decreased significantly (P<.001) in participants taking low-dose estrogen compared with placebo. Estradiol, estrone, and sex hormone–binding globulin levels increased in the estrogen-treated group compared with placebo. The adverse effect profile was similar; specifically, there were no statistically significant differences in breast tenderness, changes in endometrial thickness or pathological effects, or annual mammographic results between the 2 groups. The number of abnormal mammograms over 3 years was 15 for the low-dose estrogen group and 10 for the placebo group (8 occurred at baseline) (P = .26). There were no reports of breast cancer during the study.
Conclusions In older women, a dosage of 0.25 mg/d of 17-estradiol increased bone density of the hip, spine, and total body, and reduced bone turnover, with minimal adverse effects. Future studies evaluating the effect of low-dose estrogen on fractures are indicated.
Author Affiliations: Center on Aging (Drs Prestwood and Kenny and Ms Kleppinger), and Department of Community Medicine, Division of Biostatistics (Dr Kulldorff), University of Connecticut Health Center, Farmington.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Soy proteins and isoflavones affect bone mineral density in older women: a randomized controlled trial
Kenny et al.
Am. J. Clin. Nutr. 2009;90:234-242.
ABSTRACT
| FULL TEXT
Dehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on bone
Weiss et al.
Am. J. Clin. Nutr. 2009;89:1459-1467.
ABSTRACT
| FULL TEXT
Higher muscle protein synthesis in women than men across the lifespan, and failure of androgen administration to amend age-related decrements
Henderson et al.
FASEB J. 2009;23:631-641.
ABSTRACT
| FULL TEXT
DHEA in Elderly Women and DHEA or Testosterone in Elderly Men
Nair et al.
NEJM 2006;355:1647-1659.
ABSTRACT
| FULL TEXT
The Prenylflavonoid Isoxanthohumol from Hops (Humulus lupulus L.) Is Activated into the Potent Phytoestrogen 8-Prenylnaringenin In Vitro and in the Human Intestine
Possemiers et al.
J. Nutr. 2006;136:1862-1867.
ABSTRACT
| FULL TEXT
Effects of Exemestane Administered for 2 Years Versus Placebo on Bone Mineral Density, Bone Biomarkers, and Plasma Lipids in Patients With Surgically Resected Early Breast Cancer
Lonning et al.
JCO 2005;23:5126-5137.
ABSTRACT
| FULL TEXT
A Randomized Placebo-Controlled Trial of Short-Term Graded Transdermal Estradiol in Healthy Gonadotropin-Releasing Hormone Agonist-Suppressed Pre- and Postmenopausal Women: Effects on Serum Markers of Bone Turnover, Insulin-Like Growth Factor-I, and Osteoclastogenic Mediators
Liu et al.
J. Clin. Endocrinol. Metab. 2005;90:1953-1960.
ABSTRACT
| FULL TEXT
From the library
Br J Ophthalmol 2003;87:1532-1532.
FULL TEXT
Will the Estrogen Story Change?
Journal Watch Dermatology 2003;2003:10-10.
FULL TEXT
Will the Estrogen Story Change?
JWatch Gastroenterology 2003;2003:10-10.
FULL TEXT
Hormone Therapy After the WHI: Thinking Outside the Box
JWatch Women's Health 2003;2003:1-1.
FULL TEXT
Will the Estrogen Story Change?
JWatch General 2003;2003:2-2.
FULL TEXT
The Search for Alternative Therapies for Menopausal Women: Estrogenic Effects of Herbs
Prestwood
J. Clin. Endocrinol. Metab. 2003;88:4075-4076.
FULL TEXT
|
